PharmaCyte Biotech, Inc. (PMCB)

NASDAQ: PMCB · Real-Time Price · USD

0.4208

-0.0202 (-4.58%)

Sep 28, 2026, 10:17 AM EDT - Market open

PharmaCyte Biotech Cash Flow Statement

Financials in millions USD. Fiscal year is May - April.

Millions USD. Fiscal year is May - Apr.

Operating Activities

Fiscal Year	TTM	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Jul '26 Jul 31, 2026	Apr '26 Apr 30, 2026	Apr '25 Apr 30, 2025	Apr '24 Apr 30, 2024	Apr '23 Apr 30, 2023	Apr '22 Apr 30, 2022
Net Income	-16.15	-19.42	30.66	0.33	-4.32	-4.24
Asset Writedown & Restructuring Costs	1.55	1.55	-	2	-	-
Loss (Gain) From Sale of Investments	8.82	6.06	-26.53	1.57	-	-
Stock-Based Compensation	1.07	1.13	0.48	0.67	0.65	0.11
Other Operating Activities	1.93	7.47	-8.94	-7.03	0.17	-
Change in Accounts Payable	-0.07	-0.13	0.01	0.26	-0.24	0.03
Change in Other Net Operating Assets	-1.08	-1.8	1.35	0.04	-0.05	-0.02
Operating Cash Flow	-3.94	-5.15	-2.98	-2.15	-3.79	-4.12
Operating Cash Flow Growth	-	-	-	-	-	-

Investing Activities

Fiscal Year	TTM	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Jul '26 Jul 31, 2026	Apr '26 Apr 30, 2026	Apr '25 Apr 30, 2025	Apr '24 Apr 30, 2024	Apr '23 Apr 30, 2023	Apr '22 Apr 30, 2022
Investment in Securities	-3	-3	-7	-	-	-
Other Investing Activities	5	5	-	-5	-	-
Investing Cash Flow	2	2	-7	-5	-	-

Financing Activities

Fiscal Year	TTM	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Jul '26 Jul 31, 2026	Apr '26 Apr 30, 2026	Apr '25 Apr 30, 2025	Apr '24 Apr 30, 2024	Apr '23 Apr 30, 2023	Apr '22 Apr 30, 2022
Long-Term Debt Repaid	-	-	-	-	-	-0.05
Net Debt Issued (Repaid)	-	-	-	-	-	-0.05
Issuance of Common Stock	1.05	1.05	-	0	0	87.36
Repurchase of Common Stock	-0.4	-0.4	-2.54	-28.2	-13.56	-
Preferred Dividends Paid	-0.33	-0.25	-	-	-	-
Dividends Paid	-0.33	-0.25	-	-	-	-
Financing Cash Flow	6.5	6.58	-25.03	-10.71	-13.56	87.31

Net Cash Flow

Fiscal Year	TTM	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Jul '26 Jul 31, 2026	Apr '26 Apr 30, 2026	Apr '25 Apr 30, 2025	Apr '24 Apr 30, 2024	Apr '23 Apr 30, 2023	Apr '22 Apr 30, 2022
Foreign Exchange Rate Adjustments	0	0	-0	-0	-0.01	0
Net Cash Flow	4.56	3.43	-35.01	-17.86	-17.36	83.2

Free Cash Flow

Fiscal Year	TTM	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Jul '26 Jul 31, 2026	Apr '26 Apr 30, 2026	Apr '25 Apr 30, 2025	Apr '24 Apr 30, 2024	Apr '23 Apr 30, 2023	Apr '22 Apr 30, 2022
Levered Free Cash Flow	2.57	2.22	-13.34	3.28	-3.52	-2.62
Unlevered Free Cash Flow	2.57	2.22	-13.34	3.28	-3.52	-2.62

Additional Metrics

Fiscal Year	TTM	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Jul '26 Jul 31, 2026	Apr '26 Apr 30, 2026	Apr '25 Apr 30, 2025	Apr '24 Apr 30, 2024	Apr '23 Apr 30, 2023	Apr '22 Apr 30, 2022
Cash Interest Paid	-	-	-	-	-	0
Cash Income Tax Paid	-	-	-	0	-	0
Change in Working Capital	-1.15	-1.93	1.36	0.3	-0.3	0.01

SEC Filings: 10-K · 10-Q